{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:05:50Z","timestamp":1790618750767,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018911","name":"University Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcv.2023.105445","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T23:15:35Z","timestamp":1680736535000},"page":"105445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Human pegivirus viremia in HCV\/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-0955","authenticated-orcid":false,"given":"B.A.","family":"Hlavay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ogando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Stapleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcv.2023.105445_bib0001","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/21505594.2022.2029328","article-title":"Review of human pegivirus: prevalence, transmission, pathogenesis, and clinical implication","volume":"13","author":"Yu","year":"2022","journal-title":"Virulence"},{"issue":"2","key":"10.1016\/j.jcv.2023.105445_bib0002","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/JVI.02036-15","article-title":"Divergent viruses discovered in arthropods and vertebrates revise the evolutionary history of the Flaviviridae and related viruses","volume":"90","author":"Shi","year":"2016","journal-title":"J. Virol."},{"issue":"Pt 7","key":"10.1016\/j.jcv.2023.105445_bib0003","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1099\/vir.0.000086","article-title":"Tropism of human pegivirus (formerly known as GB virus C\/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection","volume":"96","author":"Chivero","year":"2015","journal-title":"J. Gen. Virol."},{"issue":"5","key":"10.1016\/j.jcv.2023.105445_bib0004","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/cid\/ciz940","article-title":"Human pegivirus infection and lymphoma risk: a systematic review and meta-analysis","volume":"71","author":"Fama","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.jcv.2023.105445_bib0005","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/ijc.25035","article-title":"GBV-C\/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study","volume":"126","author":"Krajden","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.jcv.2023.105445_bib0006","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1158\/0008-5472.CAN-14-0209","article-title":"GBV-C infection and risk of NHL among U.S. adults","volume":"74","author":"Chang","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jcv.2023.105445_bib0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/vox.12876","article-title":"Global prevalence of human pegivirus-1 in healthy volunteer blood donors: a systematic review and meta-analysis","volume":"115","author":"Yang","year":"2020","journal-title":"Vox Sang"},{"issue":"6","key":"10.1016\/j.jcv.2023.105445_bib0008","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jhep.2008.06.024","article-title":"Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy","volume":"49","author":"Piroth","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2023.105445_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.887760","article-title":"Human pegivirus type 1: a common human virus that is beneficial in immune-mediated disease?","volume":"13","author":"Stapleton","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jcv.2023.105445_bib0010","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/0003-4819-125-9-199611010-00007","article-title":"Effect of hepatitis G virus infection on chronic hepatitis C","volume":"125","author":"Tanaka","year":"1996","journal-title":"Ann Intern. Med."},{"issue":"1","key":"10.1016\/j.jcv.2023.105445_bib0011","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/(SICI)1096-9071(199801)54:1<26::AID-JMV5>3.0.CO;2-R","article-title":"GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy","volume":"54","author":"Pawlotsky","year":"1998","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.jcv.2023.105445_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/505713","article-title":"GB virus C (GBV-C) infection in hepatitis C virus (HCV)\/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype","volume":"194","author":"Schwarze-Zander","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2023.105445_bib0013","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.virol.2014.03.018","article-title":"Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors","volume":"456-457","author":"Chowdhury","year":"2014","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.jcv.2023.105445_bib0014","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12874-022-01700-y","article-title":"Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learning","volume":"22","author":"Marathe","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"issue":"9","key":"10.1016\/j.jcv.2023.105445_bib0015","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cix126","article-title":"Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV","volume":"64","author":"Young","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.jcv.2023.105445_bib0016","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1097\/QAD.0b013e32833adbb5","article-title":"Canadian co-infection cohort study i. impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy","volume":"24","author":"Potter","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2023.105445_bib0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coviro.2014.04.012","article-title":"Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance","volume":"8","author":"Lim","year":"2014","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"10.1016\/j.jcv.2023.105445_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02729-22","article-title":"RNA-dependent RNA polymerase of the second human pegivirus exhibits a high-fidelity feature","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol. Spectr."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653223000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653223000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:17:10Z","timestamp":1761362230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653223000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":18,"alternative-id":["S1386653223000689"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2023.105445","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human pegivirus viremia in HCV\/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2023.105445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105445"}}